drugset / Trial / NCT05130866
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in participants with progressive NF2 mutated meningiomas.
Timeline
- Start
- 2022-06-20
- Primary completion
- 2025-08-18
- Completion
- 2025-08-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AR-42 | Small molecule | 40 mg | Oral |
| Subject | AR-42 | Small molecule | 60 mg | Oral |